People · Operator
Named in public records as an officer, director or promoter · active 2019–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Biotricity Inc. | — | Biotechnology | Series A | $10.6M | $6.0M | 2019 |
John Ayanoglou at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Ayanoglou on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve Salmon | 1 | 6 |
| David Rosa | 1 | 5 |
| David A. Rosa | 1 | 5 |
| Norman Betts | 1 | 3 |
| Patricia Kennedy | 1 | 3 |
| Ronald A. McClurg | 1 | 2 |
| Norman M. Betts, M.D. | 1 | 1 |
| Chester A. White | 1 | 1 |
| Waqaas Al-Siddiq | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.